Down-regulation of vascular GLP-1 receptor expression in human subjects with obesity.

Scientific Reports
Tomohiko KimuraHideaki Kaneto

Abstract

It has been thought that incretin signaling prevents arteriosclerosis, and very recently anti-arteriosclerotic effects through GLP-1 receptor were finally demonstrated in clinical human study. The purpose of this study was to investigate how vascular GLP-1 receptor expression is influenced in human subjects. First, we evaluated GLP-1 receptor expression in human arteries in immunostaining. Next, we separated the artery into the intima and media, and evaluated gene expression levels of various factors. We divided the subjects into obesity and non-obesity group and compared their expression levels between them. Finally, we evaluated which factors determine vascular GLP-1 receptor expression. GLP-1 receptor expression in intima and media was lower in obesity group compared to non-obesity group which was correlated with the alteration of TCF7L2 expression. Multiple regression analyses showed that BMI was an independent determining factor for GLP-1 receptor expression in the intima and media. Furthermore, using small interfering RNA method and TCF7L2-EGFP adenovirus, we showed that TCF7L2 was involved in GLP-1 receptor expression in human vascular cells. Taken together, vascular GLP-1 receptor and TCF7L2 expression was significantly...Continue Reading

References

Sep 9, 2004·American Journal of Physiology. Endocrinology and Metabolism·Thomas NyströmAke Sjöholm
Oct 12, 2007·Physiological Reviews·Jens Juul Holst
Mar 21, 2008·Trends in Molecular Medicine·Jens J HolstSten Madsbad
Apr 26, 2008·Diabetes, Obesity & Metabolism·Kasper AaboeJens Juul Holst
Sep 13, 2008·Molecular and Cellular Endocrinology·Jens Juul HolstCarolyn F Deacon
Jan 27, 2009·Diabetes·Gabriela da Silva XavierGuy A Rutter
Jan 11, 2011·Biochemical and Biophysical Research Communications·Hiromasa GotoHirotaka Watada
May 13, 2011·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Tracey GaspariAnthony E Dear
Sep 5, 2012·Nature Reviews. Endocrinology·Juris J Meier
Dec 12, 2012·European Journal of Pharmacology·Yoichiro HirataMasataka Sata
Jan 9, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J J Holst
Oct 31, 2014·Human Molecular Genetics·Ryan K MitchellGabriela Da Silva Xavier
Mar 21, 2015·International Journal of Molecular Sciences·Hideaki Kaneto, Taka-aki Matsuoka
Dec 3, 2015·Diabetes Care·Tomoya MitaUNKNOWN Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators

❮ Previous
Next ❯

Citations

Nov 6, 2020·Journal of Diabetes Investigation·Tomohiko Kimura, Kohei Kaku
Dec 16, 2020·Endocrine Reviews·Brent A McLeanDaniel J Drucker
Nov 3, 2020·BMJ Open Diabetes Research & Care·Charles-Henri MalbertKaren L Jones
Feb 23, 2021·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·Zhensheng ZhangXiao Xu
Apr 4, 2021·International Journal of Molecular Sciences·Hideaki KanetoKohei Kaku
Oct 7, 2021·Journal of Cellular Physiology·Laura Del Bosque-PlataClaudia Gragnoli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease
Tomohiko KimuraHideaki Kaneto
Prensa médica argentina
J L Rodríguez-Miñón
MMW, Münchener medizinische Wochenschrift
M Marshall
© 2022 Meta ULC. All rights reserved